Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 4.57% and Operating profit at -5.39% over the last 5 years
2
The company has declared Negative results for the last 6 consecutive quarters
3
With ROE of 10.36%, it has a expensive valuation with a 4.15 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,546 Million (Small Cap)
40.00
NA
2.33%
-0.69
10.36%
4.15
Revenue and Profits:
Net Sales:
90 Million
(Quarterly Results - Jun 2025)
Net Profit:
20 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.6%
0%
6.6%
6 Months
5.16%
0%
5.16%
1 Year
-4.09%
0%
-4.09%
2 Years
-30.23%
0%
-30.23%
3 Years
-48.24%
0%
-48.24%
4 Years
-68.16%
0%
-68.16%
5 Years
-48.33%
0%
-48.33%
Yantai Zhenghai Bio-Tech Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.57%
EBIT Growth (5y)
-5.39%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.72
Sales to Capital Employed (avg)
0.43
Tax Ratio
10.86%
Dividend Payout Ratio
60.69%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
62.58%
ROE (avg)
17.86%
Valuation key factors
Factor
Value
P/E Ratio
40
Industry P/E
Price to Book Value
4.15
EV to EBIT
35.12
EV to EBITDA
27.58
EV to Capital Employed
11.04
EV to Sales
8.47
PEG Ratio
NA
Dividend Yield
2.33%
ROCE (Latest)
31.44%
ROE (Latest)
10.36%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
89.60
96.70
-7.34%
Operating Profit (PBDIT) excl Other Income
21.50
33.40
-35.63%
Interest
0.00
0.00
Exceptional Items
3.60
3.30
9.09%
Consolidate Net Profit
19.90
26.60
-25.19%
Operating Profit Margin (Excl OI)
176.30%
287.00%
-11.07%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -7.34% vs 36.39% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -25.19% vs 177.08% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
359.30
409.70
-12.30%
Operating Profit (PBDIT) excl Other Income
149.50
211.40
-29.28%
Interest
0.20
0.30
-33.33%
Exceptional Items
5.40
7.20
-25.00%
Consolidate Net Profit
134.60
191.00
-29.53%
Operating Profit Margin (Excl OI)
352.50%
465.10%
-11.26%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -12.30% vs -4.59% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -29.53% vs 3.02% in Dec 2023
About Yantai Zhenghai Bio-Tech Co., Ltd. 
Yantai Zhenghai Bio-Tech Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






